scholarly journals Vaccination againstChlamydiaGenital Infection Utilizing the MurineC. muridarumModel

2010 ◽  
Vol 79 (3) ◽  
pp. 986-996 ◽  
Author(s):  
Christina M. Farris ◽  
Richard P. Morrison
Keyword(s):  
Public Health ◽  
Immune Responses ◽  
Vaccine Development ◽  
Natural Infection ◽  
Public Health Problem ◽  
Genital Infection ◽  
Considerable Effort ◽  
Activity Factor ◽  
Efficacious Vaccine ◽  
Sterilizing Immunity

ABSTRACTChlamydia trachomatisgenital infection is a worldwide public health problem, and considerable effort has been expended on developing an efficacious vaccine. The murine model ofC. muridarumgenital infection has been extremely useful for identification of protective immune responses and in vaccine development. Although a number of immunogenic antigens have been assessed for their ability to induce protection, the majority of studies have utilized the whole organism, the major outer membrane protein (MOMP), or the chlamydial protease-like activity factor (CPAF). These antigens, alone and in combination with a variety of immunostimulatory adjuvants, have induced various levels of protection against infectious challenge, ranging from minimal to nearly sterilizing immunity. Understanding of the mechanisms of natural infection-based immunity and advances in adjuvant biology have resulted in studies that are increasingly successful, but a vaccine licensed for use in humans has not yet been brought to fruition. Here we review immunity to chlamydial genital infection and vaccine development using theC. muridarummodel.

scholarly journals Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes

2006 ◽  
Vol 14 (2) ◽  
pp. 182-189 ◽  
Author(s):  
David H. Holman ◽  
Danher Wang ◽  
Kanakatte Raviprakash ◽  
Nicholas U. Raja ◽  
Min Luo ◽  
...  
Keyword(s):  
Immune Responses ◽  
Dengue Virus ◽  
Vaccine Development ◽  
De Novo ◽  
Natural Infection ◽  
Hemorrhagic Fever ◽  
Virus Infections ◽  
Dengue Vaccine ◽  
Membrane Antigens ◽  
Dengue Virus Serotypes

ABSTRACT Dengue virus infections can cause hemorrhagic fever, shock, encephalitis, and even death. Worldwide, approximately 2.5 billion people live in dengue-infested regions with about 100 million new cases each year, although many of these infections are believed to be silent. There are four antigenically distinct serotypes of dengue virus; thus, immunity from one serotype will not cross-protect from infection with the other three. The difficulties that hamper vaccine development include requirements of the natural conformation of the envelope glycoprotein to induce neutralizing immune responses and the necessity of presenting antigens of all four serotypes. Currently, the only way to meet these requirements is to use a mixture of four serotypes of live attenuated dengue viruses, but safety remains a major problem. In this study, we have developed the basis for a tetravalent dengue vaccine using a novel complex adenovirus platform that is capable of expressing multiple antigens de novo. This dengue vaccine is constructed as a pair of vectors that each expresses the premembrane and envelope genes of two different dengue virus serotypes. Upon vaccination, the vaccine expressed high levels of the dengue virus antigens in cells to mimic a natural infection and induced both humoral and cellular immune responses against multiple serotypes of dengue virus in an animal model. Further analyses show the humoral responses were indeed neutralizing against all four serotypes. Our studies demonstrate the concept of mimicking infections to induce immune responses by synthesizing dengue virus membrane antigens de novo and the feasibility of developing an effective tetravalent dengue vaccine by vector-mediated expression of glycoproteins of the four serotypes.

scholarly journals The Antibody Response to Plasmodium falciparum: Cues for Vaccine Design and the Discovery of Receptor-Based Antibodies

2019 ◽  
Vol 37 (1) ◽  
pp. 225-246 ◽  
Author(s):  
Joshua Tan ◽  
Luca Piccoli ◽  
Antonio Lanzavecchia
Keyword(s):  
Public Health ◽  
Plasmodium Falciparum ◽  
Immune System ◽  
Antibody Response ◽  
Public Health Problem ◽  
Vaccine Design ◽  
Immunoglobulin Genes ◽  
And Control ◽  
Sterilizing Immunity

Plasmodium falciparum remains a serious public health problem and a continuous challenge for the immune system due to the complexity and diversity of the pathogen. Recent advances from several laboratories in the characterization of the antibody response to the parasite have led to the identification of critical targets for protection and revealed a new mechanism of diversification based on the insertion of host receptors into immunoglobulin genes, leading to the production of receptor-based antibodies. These advances have opened new possibilities for vaccine design and passive antibody therapies to provide sterilizing immunity and control blood-stage parasites.

scholarly journals Sero-evaluation of Immune Responses to Vibrio cholerae in a Postelimination Setting

2020 ◽  
Vol 7 (5) ◽  
Author(s):  
Tai The Diep ◽  
Owen Jensen ◽  
Nguyen Van Thuong ◽  
Nguyen Thi Ngoc Nhi ◽  
Nguyen Ngoc Anh Thu ◽  
...  
Keyword(s):  
Public Health ◽  
Immune Responses ◽  
Specific Antibody ◽  
Public Health Problem ◽  
Antibody Testing ◽  
Southern Vietnam ◽  
Significant Public Health Problem ◽  
Significant Public Health ◽  
Clinical Surveillance ◽  
Blood Spot

Abstract Cholera remains a significant public health problem worldwide. In settings of declining incidence, serosurveillance may be used to augment clinical surveillance. We utilized dried blood spot sampling and cholera-specific antibody testing to examine the serologic profiles of vaccinated and unvaccinated children in southern Vietnam, where cholera was recently eliminated.

scholarly journals Obesity and the increased risk for COVID-19: mechanisms and nutritional management

2020 ◽  
pp. 1-13
Author(s):  
Ana Heloneida de Araújo Morais ◽  
Thais Sousa Passos ◽  
Sancha Helena de Lima Vale ◽  
Juliana Kelly da Silva Maia ◽  
Bruna Leal Lima Maciel
Keyword(s):  
Public Health ◽  
Immune Responses ◽  
Viral Infections ◽  
Public Health Problem ◽  
Complex Problem ◽  
Low Grade ◽  
Adaptive Immune ◽  
Increased Risk ◽  
Nutritional Strategies ◽  
Worse Prognosis

Abstract The global COVID-19 (coronavirus disease 2019) pandemic has become a complex problem that overlaps with a growing public health problem, obesity. Obesity alters different components of the innate and adaptive immune responses, creating a chronic and low-grade state of inflammation. Nutritional status is closely related to a better or worse prognosis of viral infections. Excess weight has been recognised as a risk factor for COVID-19 complications. In addition to the direct risk, obesity triggers other diseases such as diabetes and hypertension, increasing the risk of severe COVID-19. The present review explains the diets that induce obesity and the importance of different foods in this process. We also review tissue disruption in obesity, leading to impaired immune responses and the possible mechanisms by which obesity and its co-morbidities increase COVID-19 morbidity and mortality. Nutritional strategies that support the immune system in patients with obesity and with COVID-19 are also discussed in light of the available data, considering the severity of the infection. The discussions held may contribute to combating this global emergency and planning specific public health policy.

scholarly journals Understanding COVID-19: From Dysregulated Immunity to Vaccination Status Quo

2021 ◽  
Vol 12 ◽  
Author(s):  
Ruby A. Escobedo ◽  
Dhiraj K. Singh ◽  
Deepak Kaushal
Keyword(s):  
Public Health ◽  
Personalized Medicine ◽  
Immune Responses ◽  
Vaccine Development ◽  
Rapid Development ◽  
Experimental Models ◽  
Status Quo ◽  
Vaccination Status ◽  
Species Barrier ◽  
Life And Death

The development of vaccines against infectious diseases has helped us battle the greatest threat to public health. With the emergence of novel viruses, targeted immunotherapeutics ranging from informed vaccine development to personalized medicine may be the very thing that separates us between life and death. Late in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), made a remarkable entrance to human civilization, being one of many to cross the species barrier. This review discusses the important aspects of COVID-19, providing a brief overview of our current understanding of dysregulated immune responses developed using various experimental models, a brief outline of experimental models of COVID-19 and more importantly, the rapid development of vaccines against COVID-19.

scholarly journals The case for a universal hepatitis C vaccine to achieve hepatitis C elimination

BMC Medicine ◽  
2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Nick Scott ◽  
David P. Wilson ◽  
Alexander J. Thompson ◽  
Eleanor Barnes ◽  
Manal El-Sayed ◽  
...  
Keyword(s):  
Public Health ◽  
Hepatitis C ◽  
Vaccine Development ◽  
Treatment As Prevention ◽  
Test And Treat ◽  
Direct Acting Antiviral ◽  
Community Transmission ◽  
Efficacious Vaccine ◽  
Health Need ◽  
Direct Acting

Abstract Background The introduction of highly effective direct-acting antiviral (DAA) therapy for hepatitis C has led to calls to eliminate it as a public health threat through treatment-as-prevention. Recent studies suggest it is possible to develop a vaccine to prevent hepatitis C. Using a mathematical model, we examined the potential impact of a hepatitis C vaccine on the feasibility and cost of achieving the global WHO elimination target of an 80% reduction in incidence by 2030 in the era of DAA treatment. Methods The model was calibrated to 167 countries and included two population groups (people who inject drugs (PWID) and the general community), features of the care cascade, and the coverage of health systems to deliver services. Projections were made for 2018–2030. Results The optimal incidence reduction strategy was to implement test and treat programmes among PWID, and in settings with high levels of community transmission undertake screening and treatment of the general population. With a vaccine available, the optimal strategy was to include vaccination within test and treat programmes, in addition to vaccinating adolescents in settings with high levels of community transmission. Of the 167 countries modelled, between 0 and 48 could achieve an 80% reduction in incidence without a vaccine. This increased to 15–113 countries if a 75% efficacious vaccine with a 10-year duration of protection were available. If a vaccination course cost US$200, vaccine use reduced the cost of elimination for 66 countries (40%) by an aggregate of US$7.4 (US$6.6–8.2) billion. For a US$50 per course vaccine, this increased to a US$9.8 (US$8.7–10.8) billion cost reduction across 78 countries (47%). Conclusions These findings strongly support the case for hepatitis C vaccine development as an urgent public health need, to ensure hepatitis C elimination is achievable and at substantially reduced costs for a majority of countries.

DISTRIBUTION OF TRIATOMINES (HETEROPTERA: REDUVIIDAE) ASSOCIATED WITH HUMAN HABITATION AND POTENTIAL RISK AREAS IN SIX STATES OF THE MEXICAN REPUBLIC

2020 ◽  
Vol 5 ◽  
Author(s):  
José Ismael Benítez-Alva ◽  
Herón Huerta ◽  
Juan Luis Téllez-Rendón
Keyword(s):  
Public Health ◽  
Latin America ◽  
Trypanosoma Cruzi ◽  
Potential Risk ◽  
Health Problem ◽  
Natural Infection ◽  
Public Health Problem ◽  
Distribution Maps ◽  
Risk Areas ◽  
Human Habitation

Chagas disease is a real public health problem in Latin America, caused by the flagellate protozoan<br />Trypanosoma cruzi and described by Carlos Chagas in 1909. T. cruzi is transmitted by bloodsucking<br />insects of the subfamily Triatominae which thrive in sylvatic, peridomestic, and domestic habitats,<br />being in the latter two a potential risk to public health because of their role as vectors. We review the<br />distribution of triatomines associated with human habitation and their natural infection with T. cruzi<br />from the states of Aguascalientes, Chiapas, Guerrero, Jalisco, Michoacán, and Oaxaca. Based on<br />samples received in the Laboratory of Entomology of the Institute of Epidemiological Diagnosis and<br />Reference (InDRE-SSA) during the period 2006 to 2010, distribution maps and stratification of potential<br />areas of risk were made. A total of 1910 specimens of seven species of triatomines were identified.<br />Triatoma barberi, Meccus longipennis and M. pallidipennis were the species with the highest rate of<br />infection with T. cruzi; M. pallidipennis and T. dimidiata were the most widely distributed species.

scholarly journals Waning Immunity and Microbial Vaccines—Workshop of the National Institute of Allergy and Infectious Diseases

2017 ◽  
Vol 24 (7) ◽  
Author(s):  
Xin-Xing Gu ◽  
Stanley A. Plotkin ◽  
Kathryn M. Edwards ◽  
Alessandro Sette ◽  
Kingston H. G. Mills ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Immune Responses ◽  
New Technologies ◽  
Vaccine Development ◽  
Natural Infection ◽  
Complex Life Cycle ◽  
Future Research ◽  
Content Type ◽  
Waning Immunity

ABSTRACT Since the middle of the 20th century, vaccines have made a significant public health impact by controlling infectious diseases globally. Although long-term protection has been achieved with some vaccines, immunity wanes over time with others, resulting in outbreaks or epidemics of infectious diseases. Long-term protection against infectious agents that have a complex life cycle and antigenic variation remains a key challenge. Novel strategies to characterize the short- and long-term immune responses to vaccines and to induce immune responses that mimic natural infection have recently emerged. New technologies and approaches in vaccinology, such as adjuvants, delivery systems, and antigen formulations, have the potential to elicit more durable protection and fewer adverse reactions; together with in vitro systems, these technologies have the capacity to model and accelerate vaccine development. The National Institute of Allergy and Infectious Diseases (NIAID) held a workshop on 19 September 2016 that focused on waning immunity to selected vaccines (for Bordetella pertussis, Salmonella enterica serovar Typhi, Neisseria meningitidis, influenza, mumps, and malaria), with an emphasis on identifying knowledge gaps, future research needs, and how this information can inform development of more effective vaccines for infectious diseases.

scholarly journals The Recall Response Induced by Genital Challenge with Chlamydia muridarum Protects the Oviduct from Pathology but Not from Reinfection

2012 ◽  
Vol 80 (6) ◽  
pp. 2194-2203 ◽  
Author(s):  
Melissa M. Riley ◽  
Matthew A. Zurenski ◽  
Lauren C. Frazer ◽  
Catherine M. O'Connell ◽  
Charles W. Andrews ◽  
...  
Keyword(s):  
T Cell ◽  
Vaccine Development ◽  
T Cell Response ◽  
Genital Infection ◽  
Content Type ◽  
Chlamydia Muridarum ◽  
Tube Obstruction ◽  
Fallopian Tube Obstruction ◽  
Tissue Site ◽  
Sterilizing Immunity

ABSTRACTThe significant morbidities of ectopic pregnancy and infertility observed in women afterChlamydia trachomatisgenital infection result from ascension of the bacteria from the endocervix to the oviduct, where an overly aggressive inflammatory response leads to chronic scarring and Fallopian tube obstruction. A vaccine to prevent chlamydia-induced disease is urgently needed. An important question for vaccine development is whether sterilizing immunity at the level of the oviduct is essential for protection because of the possibility that a chlamydial component drives a deleterious anamnestic T cell response upon oviduct reinfection. We show that mice inoculated with attenuated plasmid-cured strains ofChlamydia muridarumare protected from oviduct pathology upon challenge with wild-typeC. muridarumNigg despite induction of a response that did not prevent reinfection of the oviduct. Interestingly, repeated abbreviated infections with Nigg also elicited recall responses that protected the oviduct from pathology despite low-level reinfection of this vulnerable tissue site. Challenged mice displayed significant decreases in tissue infiltration of inflammatory leukocytes with marked reductions in frequencies of neutrophils but significant increases in frequencies of CD4 Th1 and CD8 T cells. An anamnestic antibody response was also detected. These data indicate that exposure to a live attenuated chlamydial vaccine or repeated abbreviated genital infection with virulent chlamydiae promotes anamnestic antibody and T cell responses that protect the oviduct from pathology despite a lack of sterilizing immunity at the site.

scholarly journals Accelerator or Brake: Immune Regulators in Malaria

2020 ◽  
Vol 10 ◽  
Author(s):  
Chunmei Cai ◽  
Zhiqiang Hu ◽  
Xiao Yu
Keyword(s):  
Public Health ◽  
Infectious Disease ◽  
Immune Responses ◽  
Vaccine Development ◽  
Current Understanding ◽  
Regulatory Mechanisms ◽  
Contributing Factors ◽  
Host Immune Responses ◽  
Life Threatening

Malaria is a life-threatening infectious disease, affecting over 250 million individuals worldwide each year, eradicating malaria has been one of the greatest challenges to public health for a century. Growing resistance to anti-parasitic therapies and lack of effective vaccines are major contributing factors in controlling this disease. However, the incomplete understanding of parasite interactions with host anti-malaria immunity hinders vaccine development efforts to date. Recent studies have been unveiling the complexity of immune responses and regulators against Plasmodium infection. Here, we summarize our current understanding of host immune responses against Plasmodium-derived components infection and mainly focus on the various regulatory mechanisms mediated by recent identified immune regulators orchestrating anti-malaria immunity.

Sign in / Sign up

Export Citation Format

Share Document